[go: up one dir, main page]

MX2015000008A - Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. - Google Patents

Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.

Info

Publication number
MX2015000008A
MX2015000008A MX2015000008A MX2015000008A MX2015000008A MX 2015000008 A MX2015000008 A MX 2015000008A MX 2015000008 A MX2015000008 A MX 2015000008A MX 2015000008 A MX2015000008 A MX 2015000008A MX 2015000008 A MX2015000008 A MX 2015000008A
Authority
MX
Mexico
Prior art keywords
keratin
diagnosis
cancer
prostata
markers
Prior art date
Application number
MX2015000008A
Other languages
English (en)
Other versions
MX360236B (es
Inventor
Niven Rajin Narain
Rangaprasad Sarangarajan
Vivek K Vishnudas
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of MX2015000008A publication Critical patent/MX2015000008A/es
Publication of MX360236B publication Critical patent/MX360236B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/57555—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención proporciona métodos de diagnóstico, monitoreo y pronóstico del cáncer de próstata usando uno o más de queratina 4, queratina 7, queratina 8, queratina 15, queratina 18, queratina 19, tubulin-beta 3, filamina B y LY9 y PSA. La invención proporciona equipos para practicar los métodos de la invención.
MX2015000008A 2012-06-27 2013-06-27 Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. MX360236B (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261665201P 2012-06-27 2012-06-27
US201261672090P 2012-07-16 2012-07-16
US201261673094P 2012-07-18 2012-07-18
US201261702523P 2012-09-18 2012-09-18
US201261718081P 2012-10-24 2012-10-24
US201261718064P 2012-10-24 2012-10-24
US201261718080P 2012-10-24 2012-10-24
PCT/US2013/048373 WO2014004931A1 (en) 2012-06-27 2013-06-27 Use of markers in the diagnosis and treatment of prostate cancer

Publications (2)

Publication Number Publication Date
MX2015000008A true MX2015000008A (es) 2015-04-10
MX360236B MX360236B (es) 2018-10-26

Family

ID=49783880

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000008A MX360236B (es) 2012-06-27 2013-06-27 Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.

Country Status (15)

Country Link
US (3) US20140038838A1 (es)
EP (1) EP2867375B1 (es)
JP (2) JP6352909B2 (es)
KR (1) KR20150023904A (es)
CN (1) CN104583422A (es)
AU (1) AU2013284448B2 (es)
BR (1) BR112014032728A2 (es)
CA (1) CA2877721A1 (es)
EA (1) EA201492284A1 (es)
ES (1) ES2720763T3 (es)
IL (1) IL236482A0 (es)
MX (1) MX360236B (es)
NZ (1) NZ703411A (es)
SG (1) SG11201408651TA (es)
WO (1) WO2014004931A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150333A1 (es) 2012-03-05 2015-03-25 Arctic Partners Ab Oy Metodos y aparatos para predecir riesgo de cancer de prostata y volumen de glandula prostatica
AU2015215008B2 (en) * 2014-02-05 2019-11-28 Fujirebio Diagnostics Ab Composition and method for detecting malignant neoplastic disease
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
HUE065029T2 (hu) 2014-03-28 2024-04-28 Opko Diagnostics Llc A prosztatarák diagnosztikával kapcsolatos készítmények és eljárások
CN107428821B (zh) 2014-12-08 2022-06-24 博格有限责任公司 包括细丝蛋白a的标志物在诊断和治疗前列腺癌中的用途
UA124522C2 (uk) 2015-03-27 2021-10-05 Опко Дайегностікс, Елелсі Спосіб кількісної оцінки рівнів простатичного антигену
WO2017210562A1 (en) * 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
WO2018009834A1 (en) * 2016-07-07 2018-01-11 Berg Llc Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer
WO2018189292A1 (en) * 2017-04-13 2018-10-18 Institut National De La Sante Et De La Recherche Medicale Biomarkers of castration-resistant prostatic cells
KR102405789B1 (ko) * 2018-08-24 2022-06-07 고려대학교 세종산학협력단 키누레닌 경로 대사체를 포함하는 전립선암 진단용 바이오마커 조성물
CN109608537B (zh) * 2018-12-12 2020-09-15 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p2及其应用
CN109608536B (zh) * 2018-12-12 2020-09-15 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p3及其应用
KR102497196B1 (ko) 2020-09-08 2023-02-07 (주)유로테크 전립선암 진단 점수 계산 방법 및 그 용도
CN114134223B (zh) * 2021-12-02 2022-10-11 青岛市中心血站 一种用于丙型肝炎病毒相关肝纤维化的血液检测试剂盒
CN114460297A (zh) * 2022-01-17 2022-05-10 珠海中科先进技术研究院有限公司 一种用于检测血液中循环前列腺上皮细胞的免疫荧光试剂盒及其使用方法

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942999C2 (de) 1989-12-27 1997-12-18 Progen Biotechnik Gmbh Verfahren zum Nachweis von malignen Erkrankungen
DE4208422A1 (de) 1992-03-16 1993-09-30 Boehringer Mannheim Gmbh Verfahren zum Nachweis von Mikrometastasen ekto- oder entodermaler Tumoren
CA2250118C (en) 1996-03-26 2009-09-29 Michael S. Kopreski Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US6107103A (en) * 1996-10-15 2000-08-22 Procyon Bropharma Inc. Assay for PSP94 protein
WO1999014372A1 (en) 1997-09-15 1999-03-25 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
CA2347625A1 (en) 1998-10-22 2000-04-27 Richard A. Shimkets Genes and proteins predictive and therapeutic for renal disease and associated disorders
WO2000040749A2 (en) 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
US7368527B2 (en) 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
JP2003535580A (ja) 2000-03-27 2003-12-02 トーマス ジェファーソン ユニバーシティ 高特異性マーカー検出
AU2001285047A1 (en) 2000-08-16 2002-02-25 Chiron Corporation Human genes and gene expression products
US20030073144A1 (en) 2001-01-30 2003-04-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
DE60232059D1 (de) * 2001-03-01 2009-06-04 Epigenomics Ag Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene
EP3115470B1 (en) 2002-03-13 2018-07-18 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040029151A1 (en) 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
WO2003097878A1 (en) 2002-05-21 2003-11-27 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
JP2006513700A (ja) 2002-09-25 2006-04-27 ジェネンテック・インコーポレーテッド 乾癬の治療のための新規組成物と方法
US20050259483A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US20040109863A1 (en) * 2002-12-04 2004-06-10 Peter Emtage Methods of therapy and diagnosis using targeting of cells that express Ly-9
DE10259703A1 (de) 2002-12-19 2004-07-08 Ivonex Gmbh Trennungsverfahren
EP2474630B1 (en) 2002-12-20 2016-04-27 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
WO2004076614A2 (de) * 2003-02-27 2004-09-10 Bernd Hinzmann Humane nukleinsäuresequenzen aus prostatakarzinomen
CA2519630A1 (en) 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
JP2007507222A (ja) 2003-05-28 2007-03-29 ゲノミック ヘルス， インコーポレイテッド 化学療法に対する応答を予測するための遺伝子発現マーカー
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
EP1522594A3 (en) 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
ITPD20030264A1 (it) 2003-10-30 2005-04-30 Xeptagen Spa Metodo di diagnosi altamente specifico per neoplasie
CN1743849A (zh) 2004-09-03 2006-03-08 上海透景生命科技有限公司 一种多肿瘤标志物并行检测的方法及试剂盒
US20060057127A1 (en) 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
US20060063214A1 (en) 2004-09-17 2006-03-23 Ozge Alper Methods and compositions for diagnosing neoplastic disease
CA2586201A1 (en) 2004-11-03 2006-05-11 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8093011B2 (en) 2005-03-16 2012-01-10 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US9234897B2 (en) 2005-03-31 2016-01-12 Two Cells Co., Ltd Method for distinguishing mesenchymal stem cell using molecular marker and use thereof
EP1910564A1 (en) 2005-05-13 2008-04-16 Duke University Gene expression signatures for oncogenic pathway deregulation
US8609345B2 (en) * 2005-05-25 2013-12-17 Expression Pathology Incorporated Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2006127860A2 (en) 2005-05-25 2006-11-30 Expression Pathology, Inc. Multiplex method for increased proteomic coverage from histopathologically processed biological samples using liquid tissue preparations
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2612021A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1734118A1 (en) 2005-06-15 2006-12-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening
US7842466B1 (en) 2005-09-16 2010-11-30 Celera Corporation Colon disease targets and uses thereof
CA2625403A1 (en) 2005-10-17 2007-04-26 Institute For System Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070220621A1 (en) 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
US20070122856A1 (en) 2005-11-10 2007-05-31 Aurelium Biopharma Inc. Tissue diagnostics for ovarian cancer
US20080305558A1 (en) 2005-12-19 2008-12-11 Ruth Louise Loveday Cancer Screening Test
US20070231822A1 (en) 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
JP4968577B2 (ja) * 2006-04-11 2012-07-04 エフ．ホフマン−ラ ロシュ アーゲー サイトケラチン１９（ＣＫ１９）ｍＲＮＡの迅速測定法、並びにそのためのプライマー及びプローブ
US20080003624A1 (en) 2006-06-13 2008-01-03 Sysmex Corporation Cancer metastasis determination method
US7901902B2 (en) 2006-07-27 2011-03-08 Biosante Pharmaceuticals, Inc. Methods and compositions for identifying a cellular immune response against prostate cancer
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
US8642349B1 (en) 2006-08-11 2014-02-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial neural network proteomic tumor classification
US8748108B2 (en) 2006-09-05 2014-06-10 Abbvie Inc. Biomarkers for identifying patient classes
ES2375453T3 (es) 2006-09-07 2012-03-01 Universitätsklinikum Hamburg-Eppendorf Método para la detección de células epiteliales cancerosas utilizando citoqueratinas liberadas como marcadores para dichas células.
US9353415B2 (en) 2006-12-19 2016-05-31 Thomson Reuters (Scientific) Llc Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
ATE555212T1 (de) * 2007-03-02 2012-05-15 Biosante Pharmaceuticals Inc Verfahren und zusammensetzungen zur identifizierung von prostatakrebs oder einer humoralen immunantwort gegen prostatakrebs
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2008121307A2 (en) * 2007-03-28 2008-10-09 Cell Genesys, Inc. Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
EP2145021A2 (en) 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US20090221004A1 (en) 2007-06-01 2009-09-03 Anita Lim Hong Caspase-cleavage anti-keratin antibodies for detection of apoptosis
EP2201134B1 (en) 2007-09-19 2018-11-21 The Research Foundation of State University of New York Gene expression signatures in enriched tumor cell samples
EP2208066A2 (en) 2007-10-03 2010-07-21 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20090105167A1 (en) 2007-10-19 2009-04-23 Duke University Predicting responsiveness to cancer therapeutics
MX2010004671A (es) 2007-12-10 2010-05-27 Hoffmann La Roche Seprasa como marcador para cancer.
ES2703363T3 (es) 2008-02-01 2019-03-08 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico y pronóstico de tumores cerebrales
US8008032B2 (en) 2008-02-25 2011-08-30 Cellective Dx Corporation Tagged ligands for enrichment of rare analytes from a mixed sample
CA2730614A1 (en) 2008-07-16 2010-01-21 Dana-Farber Cancer Institute Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
US9127078B2 (en) 2008-07-21 2015-09-08 The Trustees Of The University Of Pennsylvania Methods and compositions using splicing regulatory proteins involved in tumor suppression
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
IT1391619B1 (it) 2008-11-04 2012-01-11 Silicon Biosystems Spa Metodo per l'individuazione, selezione e analisi di cellule tumorali
WO2013022995A2 (en) 2011-08-08 2013-02-14 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
JP5172020B2 (ja) 2008-11-12 2013-03-27 エフ．ホフマン−ラ ロシュ アーゲー 癌のマーカーとしてのｐａｃａｐ
CA2745961A1 (en) * 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
CA2747942C (en) 2008-12-22 2016-12-06 F. Hoffmann-La Roche Ag Armet as a marker for cancer
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
JP2012100536A (ja) 2009-03-02 2012-05-31 Genescience Co Ltd 血液試料に含まれる単核球細胞を用いた癌関連遺伝子の発現解析による癌の遺伝子検査方法
US20110311443A1 (en) 2009-03-06 2011-12-22 Klaus Tschira Stiftung Ggmbh Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
US10815517B2 (en) 2009-04-28 2020-10-27 Roche Diagnostics Operations, Inc. Use of DPPIV/seprase as a marker for cancer
JP5892794B2 (ja) * 2009-10-02 2016-03-23 学校法人 久留米大学 癌患者に対する免疫療法の治療効果および／または免疫療法後の予後の予測方法、ならびに該方法に用いる遺伝子セットおよびキット
WO2011053837A1 (en) 2009-10-29 2011-05-05 King Kutter, Inc. Stump cutter
EP2335838B1 (en) 2009-12-18 2012-09-26 Deutsche Post AG Sorting system and method using a portable device
US20130095503A1 (en) 2010-01-05 2013-04-18 University Of Cincinnati Serum spla2-iia as diagnosis marker for prostate and lung cancer
US20110177525A1 (en) 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
US8664472B2 (en) 2010-04-28 2014-03-04 Sesaco Corporation Pygmy sesame plants for mechanical harvesting
EP2390665A1 (en) * 2010-05-27 2011-11-30 Atlas Antibodies AB Prostate cancer biomarkers
WO2012006634A2 (en) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
US8557777B2 (en) 2010-07-09 2013-10-15 The Board Of Trustees Of The University Of Illinois Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
EP2598873A4 (en) * 2010-07-28 2013-11-20 Metabolon Inc BIOMARKERS FOR PROSTATE CANCER AND METHOD FOR THEIR USE
WO2012021969A1 (en) * 2010-08-16 2012-02-23 Mount Sinai Hospital Markers of the male urogenital tract
CA2808417A1 (en) * 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2012031374A1 (zh) 2010-09-09 2012-03-15 北京同为时代生物技术有限公司 用于诊断上皮源性癌症的血液标志物及其单克隆抗体
SG191028A1 (en) 2010-12-06 2013-07-31 Thd Spa Method for the diagnosis of a carcinoma and uses thereof
JP2014501388A (ja) 2010-12-24 2014-01-20 マップ ダイアグノースティックス ピーティーワイ エルティーディー 選択反応モニタリング（ｓｒｍ）による癌および他の病理学的実体のタンパク質プロファイル
WO2012101283A1 (en) 2011-01-28 2012-08-02 Biosystems International Sas Combinatorial biomarkers for clinical applications in lung cancer patient management
US9926601B2 (en) 2011-02-24 2018-03-27 Massachusetts Institute Of Technology Alternatively spliced mRNA isoforms as prognostic indicators for metastatic cancer
KR101320633B1 (ko) 2011-05-25 2013-10-30 엠앤디 (주) 실시간 중합반응을 이용한 암의 진단을 위한 정보제공방법 및 이를 위한 암 진단용 키트
WO2012135397A2 (en) 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
WO2012174256A2 (en) 2011-06-17 2012-12-20 The Regents Of The University Of Michigan Dna methylation profiles in cancer
EP2551673B1 (en) 2011-07-26 2016-01-20 Universidad de Salamanca Methods for the detection of cancer infiltration of the central nervous system
CN104081202A (zh) 2011-09-12 2014-10-01 克里蒂科斯有限责任公司 检测靶分子的非侵入性方法
EP2823306A4 (en) 2012-03-09 2015-11-11 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
ES2875535T3 (es) 2012-03-29 2021-11-10 Biogen Ma Inc Biomarcadores para su uso en aplicaciones de terapia de integrina
US20130317083A1 (en) 2012-05-04 2013-11-28 Thomas Jefferson University Non-coding transcripts for determination of cellular states
TWI468519B (zh) 2012-09-05 2015-01-11 Univ China Medical Methods of detecting squamous cell carcinoma in vitro
US20150226744A1 (en) 2012-09-17 2015-08-13 Ait Austrian Institute Of Technology Gmbh Colon Cancer Diagnostic Method and Means
US9201061B2 (en) 2013-02-26 2015-12-01 Industry-University Cooperation Foundation Hanyang University KRT19 stabilizing HER2 and use thereof
WO2014160499A2 (en) 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
SE538211C2 (sv) 2013-04-05 2016-04-05 Idl Biotech Ab Metod för detektering av cytokeratin 8, 18 och/eller 19 och/eller lösliga fragment därav
US20150079590A1 (en) 2013-09-18 2015-03-19 Beth Israel Deaconess Medical Center, Inc. Characterization and analysis of the composition and dynamics of the mammalian riboproteome
CN108627651A (zh) 2013-09-20 2018-10-09 阿斯图特医药公司 用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物

Also Published As

Publication number Publication date
ES2720763T3 (es) 2019-07-24
IL236482A0 (en) 2015-02-26
EP2867375A4 (en) 2016-06-01
CN104583422A (zh) 2015-04-29
AU2013284448A1 (en) 2015-01-22
HK1209792A1 (en) 2016-04-08
JP2018163164A (ja) 2018-10-18
US20140038838A1 (en) 2014-02-06
CA2877721A1 (en) 2014-01-03
KR20150023904A (ko) 2015-03-05
US20180031563A1 (en) 2018-02-01
EP2867375A1 (en) 2015-05-06
EP2867375B1 (en) 2019-02-27
JP6581247B2 (ja) 2019-09-25
US9797905B2 (en) 2017-10-24
WO2014004931A1 (en) 2014-01-03
JP2015523569A (ja) 2015-08-13
SG11201408651TA (en) 2015-01-29
EA201492284A1 (ru) 2015-11-30
BR112014032728A2 (pt) 2017-11-28
US20160178632A1 (en) 2016-06-23
JP6352909B2 (ja) 2018-07-04
NZ703411A (en) 2017-09-29
MX360236B (es) 2018-10-26
AU2013284448B2 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
MX2015000008A (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
LT4303583T (lt) Csf1r inhibitoriai, skirti panaudoti gydant tenosinovinius gigantinių ląstelių navikus
CY1123716T1 (el) Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
ECSP15026557A (es) Compuestos y sus métodos de empleo
MX2015011774A (es) Biomarcadores y metodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
CR20150368A (es) Inhibidores de histona desmetilasa
GEAP202114132A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MX383670B (es) Nuevos marcadores de la diferenciación de th17 para el acné y usos de los mismos.
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
MX2017005553A (es) Terapia de combinacion para cancer.
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
MX380146B (es) Inhibidores mk2 y usos de los mismos.
NZ601065A (en) Wnt antagonists and methods of treatment and screening
MX354217B (es) Composiciones y metodos para el tratamiento de leucemia.
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
CL2016002798A1 (es) Compuestos derivados de triciclos nitrogenados que contienen una naftiridina condensada con un bencimidazol y su uso como inhibidores de la proliferación celular para el tratamiento del cáncer de pulmón, colorrectal, hígado, páncreas, ganglio linfático, colon, próstata, cerebro, cabeza y cuello, piel, riñón sangre o corazón.
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
DK3065764T6 (da) Mini-gastrin-analog, især til anvendelse i CCK-2-receptor-positive tumordiagnoser og/eller -behandling
EA201691314A1 (ru) Терапевтические способы и композиции
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
EP4513187A3 (en) Methods of detecting prostate cancer

Legal Events

Date Code Title Description
FG Grant or registration